FibroGen fibrogen.com


Public list: BIO 2016 (619) Pharma Startups (4733) Cancer Therapeutics (1136)

FibroGen is a biotechnology company focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. FibroGen's FG-3019 fully human monoclonal antibody is in clinical development for treatment of idiopathic pulmonary fibrosis and other proliferative diseases, including pancreatic cancer and liver fibrosis. Roxadustat (FG-4592), FibroGen's small molecule inhibitor of hypoxia-inducible factor (HIF) ...Show all

FibroGen is a biotechnology company focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. FibroGen's FG-3019 fully human monoclonal antibod...Show all

Company (IPO / Went public)

Phone: 415-978-1200

Fax:

409 Illinois Street

San Francisco, 94158
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
FibroGen $313.3M Nov 14, 2014
Amplimmune Immunology $20M Oct 7, 2013
BioMimetic Therapeutics $92M Mar 2, 2013
See all 14 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related FibroGen Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 26 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors
See all 14 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Crystalline forms of a prolyl hydroxylase inhibitor May 18, 2016 Mar 20, 2018 Patent
Enhanced erythropoiesis and iron metabolism Nov 19, 2013 Mar 20, 2018 Patent
Compounds and methods for treatment of stroke Jul 11, 2011 Oct 03, 2017 Patent
Process for making isoquinoline compounds Mar 17, 2016 Jul 18, 2017 Patent
Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase Feb 12, 2016 Jul 04, 2017 Patent
See all 67 patents